Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-finding Study to Evaluate the Efficacy and Safety of AC-101 Tablets in Patients With Moderately to Severely Active Ulcerative Colitis

NCT07755241 is registered in ClinicalTrials.gov with Accro Bioscience (Suzhou) Limited as lead sponsor.

NCT NCT07755241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07755241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-finding Study to Evaluate the Efficacy and Safety of AC-101 Tablets in Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Accro Bioscience (Suzhou) Limited
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 28, 2026
Completion date
February 28, 2028
Enrollment
153 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)